BioPharma Dive - Latest News

Intellia filing spurs safety concerns over CRISPR drug

Shares lost a quarter of their value after the company disclosed, in a regulator...

HHS terminates Moderna contract to develop bird flu vac...

The funding was meant to help the U.S. prepare for pandemics triggered by avian ...

Merck, Daiichi pull approval application for ADC in lun...

A therapy at the center of their $22 billion alliance failed to extend survival ...

Muscle-sparing obesity drug safe for Phase 3 trial, Ver...

The company is preparing a Phase 3 trial of enobosarm with a novel formulation t...

FDA leaders seek industry input on ‘listening tour’

Commissioner Martin Makary and two of his deputies aim to meet with drugmaker CE...

Cancer drugmaker iTeos to shut down

Weeks after shelving a TIGIT drug prospect, the biotech is seeking to sell off i...

GSK-licensed antibiotic meets goal in late-stage study

The British drugmaker may have succeeded in reviving an oral antibiotic previous...

GLP-1 prescriptions for weight loss soar, despite obsta...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped ...

Lilly to buy pain drug developer SiteOne, challenging V...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting io...

FDA sets COVID vaccine formula as RFK Jr. narrows guida...

The agency recommends manufacturers update their vaccines to target the JN.1 str...

GlycoEra raises $130M, riding interest in protein degra...

The startup is the latest beneficiary of investors’ appetite for protein-degradi...

Biogen strikes RNAi deal with City; Aurion withdraws IPO

City will receive $46 million from Biogen under the alliance. Elsewhere, Angelin...

Patient dies in trial of Rocket gene therapy for heart ...

The FDA has placed a clinical hold on the study while Rocket works with trial mo...

The transformative impact of integrated informatics pla...

Integrated informatics platforms boost R&D speed, data quality and ROI across Bi...

Navigating the evolving landscape of fill/finish: Chall...

The demand for fill/finish services has never been greater, how are CDMOs respon...

FDA panel recommends keeping COVID shots targeted to sa...

The advisory committee, which met after the agency rolled out new vaccine guidel...

Zepzelca, Tecentriq combo extends survival in hard-to-t...

Still, the therapies’ modest benefit as a maintenance therapy points to how bett...

AI tool could help doctors ID breast cancers vulnerable...

Tumors with low- and ultra-low levels of a protein called HER2 are treatable wit...

Sanofi gains experimental Alzheimer’s drug through Vigi...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the ...

House passes reconciliation bill with massive Medicaid ...

Speaker Mike Johnson negotiated a number of last minute changes to the megabill ...

Novo pressures GLP-1 compounders as FDA ban takes hold

The Danish drugmaker unveiled a series of initiatives to increase access to Wego...

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna i...

Reproductive health startup raises $65M for infertility...

Founded in 2021, ReproNovo has licensed rights to two drugs from Mereo BioPharma...

Moderna pulls application for combo COVID, flu shot

The announcement, which followed the FDA setting new guidelines on COVID vaccine...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.